1. Scrip

CAR-Ts May Be Closer Competitors To Lilly’s Jaypirca Than Fellow BTK Inhibitors

 
• By Alaric DeArment

The Loxo@Lilly drug got FDA accelerated approval in mantle cell lymphoma as the first non-covalent BTK inhibitor, enabling its use in post-BTKi disease.

FDA Approved
Lilly's Loxo announced the FDA accelerated approval of Jaypirca • Source: Shutterstock

Eli Lilly and Company's newly approved, Jaypirca (pirtobrutinib), may have the same target as BTK inhibitors already on the market, but it belongs to a different class in terms of how it will fit into the mantle cell lymphoma (MCL) treatment paradigm, and that is key to the company's commercial strategy around the drug.

Lilly's Loxo subsidiary announced 27 January that the US Food and Drug Administration granted accelerated approval of Jaypirca for patients with MCL who have received at least two prior therapies that include a BTK inhibitor

More from New Products

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.